{"entity":{"id":"nct05460273","kind":"trial","name":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)","aka":["TROPION-PanTumor02"],"tldr":"A phase 1/2 trial of Datopotamab deruxtecan in non-small-cell lung cancer and triple-negative breast cancer, run by AstraZeneca, active and no longer recruiting.","summary":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) is a phase 1/2 interventional study registered as NCT05460273 by AstraZeneca, with 119 participants enrolled, started 2022-07-11 and due to reach its primary completion in 2023-11-07. Interventions recorded: Datopotamab Deruxtecan (Dato-DXd). Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05460273","url":"https://clinicaltrials.gov/study/NCT05460273"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","tnbc","tnbc-metastatic"],"sections":[],"technologies":["adc","topoisomerase-inhibitors"],"targets":[],"drugs":["datopotamab-deruxtecan"],"companies":["astrazeneca","daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05460273","phase":"1/2","setting":"Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advanced Non-small-cell Lung Cancer, Triple-negative Breast Cancer, Gastric/Gastroesophageal Junction Cancer, Urothelial Cancer, and Other Solid Tumours (TROPION-PanTumor02)","sponsor":"AstraZeneca","started":"2022-07-11","startedType":"actual","yearReported":2025,"enrolled":119,"enrolledBasis":"registry","outcomes":[{"endpoint":"Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR)","primary":true,"unit":"%","arms":[{"name":"TNBC Cohort","n":77,"value":33.8,"note":"95% CI 23.4 to 45.4; Figures from the ClinicalTrials.gov results section (first posted 2025-06-13), not from a publication"},{"name":"NSCLC Cohort","n":40,"value":45,"note":"95% CI 29.3 to 61.5"}],"source":"https://clinicaltrials.gov/study/NCT05460273?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"months","arms":[{"name":"TNBC Cohort","n":79,"value":13.5,"note":"95% CI 10.7 to NA; Figures from the ClinicalTrials.gov results section (first posted 2025-06-13), not from a publication"},{"name":"NSCLC Cohort","n":40,"value":16.7,"note":"95% CI 13.8 to 20.4"}],"source":"https://clinicaltrials.gov/study/NCT05460273?tab=results"}]},"route":"/trials/nct05460273/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"}]}}